At the time of writing, Neurogene Inc [NGNE] stock is trading at $18.48, down -1.91%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NGNE shares have lost -7.55% over the last week, with a monthly amount drifted -15.11%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neurogene Inc [NASDAQ: NGNE] stock has seen the most recent analyst activity on June 17, 2025, when Craig Hallum initiated its Buy rating and assigned the stock a price target of $50. Previously, Robert W. Baird downgraded its rating to Neutral on May 16, 2025, and kept the price target unchanged to $24. On June 27, 2024, BMO Capital Markets initiated with a Outperform rating and assigned a price target of $65 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $54 on June 11, 2024. Leerink Partners initiated its recommendation with a Outperform and recommended $46 as its price target on April 29, 2024. William Blair started tracking with a Outperform rating for this stock on March 21, 2024, and assigned it a price target of $61. In a note dated January 08, 2024, H.C. Wainwright initiated an Buy rating and provided a target price of $45 on this stock.
For the past year, the stock price of Neurogene Inc fluctuated between $6.88 and $74.49. Currently, Wall Street analysts expect the stock to reach $34.67 within the next 12 months. Neurogene Inc [NASDAQ: NGNE] shares were valued at $18.48 at the most recent close of the market. An investor can expect a potential return of 87.61% based on the average NGNE price forecast.
Analyzing the NGNE fundamentals
According to Neurogene Inc [NASDAQ:NGNE], the company’s sales were 0.00M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at 3.44% with Operating Profit Margin at 103.45%, Pretax Profit Margin comes in at 91.24%, and Net Profit Margin reading is 91.24%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.33 and Total Capital is -0.34. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.99 points at the first support level, and at 17.49 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.99, and for the 2nd resistance point, it is at 19.50.
Ratios To Look Out For
It is important to note that Neurogene Inc [NASDAQ:NGNE] has a current ratio of 18.07. Further, the Quick Ratio stands at 18.07, while the Cash Ratio is 3.81.
Transactions by insiders
Recent insider trading involved Cobb Stuart, Chief Scientific Officer, that happened on May 14 ’25 when 6797.0 shares were sold. Officer, STUART COBB completed a deal on May 14 ’25 to buy 6797.0 shares. Meanwhile, President and CFO Cvijic Christine Mikail sold 4501.0 shares on Mar 13 ’25.
